We did not observe any changes in the serum expression of one of the miR-34a target genes, i.e., SIRT1, after UDCA treatment in PBC patients, which is consistent with observations in NAFLD patients [38]. This evidence concerns the gene SIRT1 and metabolic dysfunction-associated steatotic liver disease.